Dr. Sherif Badawy, MD

NPI: 1821355660
Total Payments
$207,866
2024 Payments
$69,509
Companies
19
Transactions
141

Payment Breakdown by Category

Consulting$157,945 (76.0%)
Other$40,214 (19.3%)
Travel$6,903 (3.3%)
Food & Beverage$2,803 (1.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $157,945 76 76.0%
Honoraria $36,120 11 17.4%
Travel and Lodging $6,903 21 3.3%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,094 4 2.0%
Food and Beverage $2,803 29 1.3%

Top Paying Companies

Company Total Records Latest Year
VERTEX PHARMACEUTICALS INCORPORATED $76,625 47 $0 (2024)
Chiesi USA, Inc. $59,827 34 $0 (2024)
Agios Pharmaceuticals, Inc. $44,311 28 $0 (2024)
BIOVERATIV THERAPEUTICS INC. $11,208 10 $0 (2019)
E.R. Squibb & Sons, L.L.C. $4,152 1 $0 (2022)
bluebird bio, Inc. $2,800 3 $0 (2023)
Global Blood Therapeutics, Inc. $2,178 3 $0 (2022)
ModernaTX, Inc. $2,125 2 $0 (2021)
TerSera Therapeutics LLC $1,597 3 $0 (2024)
Halozyme Inc $609.00 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $69,509 58 Agios Pharmaceuticals, Inc. ($44,311)
2023 $53,921 40 Chiesi USA, Inc. ($33,882)
2022 $42,316 19 Vertex Pharmaceuticals Incorporated ($20,817)
2021 $20,428 9 Vertex Pharmaceuticals Incorporated ($17,675)
2020 $10,485 5 VERTEX PHARMACEUTICALS INCORPORATED ($5,950)
2019 $11,208 10 BIOVERATIV THERAPEUTICS INC. ($11,208)

All Payment Transactions

141 individual payment records from CMS Open Payments — Page 1 of 6

Date Company Product Nature Form Amount Type
12/12/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Honoraria Cash or cash equivalent $4,900.00 General
Category: Genetically Defined Disease
12/12/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $122.31 General
Category: Genetically Defined Disease
12/12/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $118.83 General
Category: Genetically Defined Disease
12/12/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $83.33 General
Category: Genetically Defined Disease
12/11/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Honoraria Cash or cash equivalent $5,950.00 General
Category: Genetically Defined Disease
12/11/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $592.93 General
Category: Genetically Defined Disease
12/11/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $377.20 General
Category: Genetically Defined Disease
12/11/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $129.65 General
Category: Genetically Defined Disease
12/11/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $117.78 General
Category: Genetically Defined Disease
12/11/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $108.29 General
Category: Genetically Defined Disease
12/10/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Honoraria Cash or cash equivalent $2,800.00 General
Category: Genetically Defined Disease
12/10/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Consulting Fee Cash or cash equivalent $700.00 General
Category: Genetically Defined Disease
12/06/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $12.57 General
Category: Genetically Defined Disease
12/04/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Consulting Fee Cash or cash equivalent $7,105.27 General
Category: Genetically Defined Disease
12/03/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Consulting Fee Cash or cash equivalent $4,200.00 General
Category: Genetically Defined Disease
11/27/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Honoraria Cash or cash equivalent $5,950.00 General
Category: Genetically Defined Disease
11/27/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $604.95 General
Category: Genetically Defined Disease
11/27/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $280.82 General
Category: Genetically Defined Disease
11/27/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $123.01 General
Category: Genetically Defined Disease
11/27/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Travel and Lodging Cash or cash equivalent $84.36 General
Category: Genetically Defined Disease
11/27/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Food and Beverage In-kind items and services $66.10 General
Category: Genetically Defined Disease
11/26/2024 TerSera Therapeutics LLC Consulting Fee Cash or cash equivalent $599.00 General
11/22/2024 X4 Pharmaceuticals, Inc. XOLREMDI (Drug) Food and Beverage In-kind items and services $163.01 General
Category: Immunology
11/07/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Honoraria Cash or cash equivalent $1,400.00 General
Category: Genetically Defined Disease
11/07/2024 Agios Pharmaceuticals, Inc. PYRUKYND (Drug) Consulting Fee Cash or cash equivalent $875.00 General
Category: Genetically Defined Disease

About Dr. Sherif Badawy, MD

Dr. Sherif Badawy, MD is a Pediatric Hematology-Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2012. The National Provider Identifier (NPI) number assigned to this provider is 1821355660.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sherif Badawy, MD has received a total of $207,866 in payments from pharmaceutical and medical device companies, with $69,509 received in 2024. These payments were reported across 141 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($157,945).

Practice Information

  • Specialty Pediatric Hematology-Oncology
  • Other Specialties Pediatrics
  • Location Chicago, IL
  • Active Since 04/18/2012
  • Last Updated 11/12/2025
  • Taxonomy Code 2080P0207X
  • Entity Type Individual
  • NPI Number 1821355660

Products in Payments

  • FERRIPROX (Drug) $54,449
  • PYRUKYND (Drug) $44,216
  • NO PRODUCT DISCUSSED (Drug) $11,208
  • REBLOZYL (Biological) $4,315
  • SKYSONA (Drug) $2,800
  • OXBRYTA (Drug) $2,422
  • XOLREMDI (Drug) $163.01
  • Endari (Drug) $141.54
  • Gamifant (Drug) $34.54

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Hematology-Oncology Doctors in Chicago